References
- Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis:
pathological mechanisms and modern pharmacologic therapies. Bone
Res . 2018;6:15. Published 2018 Apr 27. doi:10.1038/s41413-018-0016-9
- Gadina M. Janus kinases: an ideal target for the treatment of
autoimmune diseases. J Investig Dermatol Symp Proc .
2013;16(1):S70-S72. doi:10.1038/jidsymp.2013.29
- El Jammal T, Gerfaud-Valentin M, Sève P, Jamilloux Y. Inhibition of
JAK/STAT signaling in rheumatologic disorders: The expanding
spectrum. Joint Bone Spine . 2020;87(2):119-129.
doi:10.1016/j.jbspin.2019.09.005
- Jegatheeswaran J, Turk M, Pope JE. Comparison of Janus kinase
inhibitors in the treatment of rheumatoid arthritis: a systemic
literature review. Immunotherapy. 2019 Jun;11(8):737-754. doi:
10.2217/imt-2018-0178. Epub 2019 Apr 8. PMID: 30955397.
- Tanaka Y, Kavanaugh A, Wicklund J, McInnes IB. Filgotinib, a novel
JAK1-preferential inhibitor for the treatment of rheumatoid arthritis:
An overview from clinical trials [published online ahead of print,
2021 Apr 15]. Mod Rheumatol. 2021;1-11.
doi:10.1080/14397595.2021.1902617
- Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT
Signaling as a Target for Inflammatory and Autoimmune Diseases:
Current and Future Prospects [published correction appears in Drugs.
2017 May;77(8):939] [published correction appears in Drugs. 2017
Jun 12;:]. Drugs . 2017;77(5):521-546.
doi:10.1007/s40265-017-0701-9
- Vainchenker W, Dusa A, Constantinescu SN. JAKs in pathology: role of
Janus kinases in hematopoietic malignancies and
immunodeficiencies. Semin Cell Dev Biol . 2008;19(4):385-393.
doi:10.1016/j.semcdb.2008.07.002
- Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK
selectivity and the implications for clinical inhibition of
pharmacodynamic cytokine signalling by filgotinib, upadacitinib,
tofacitinib and baricitinib [published online ahead of print, 2021
Mar 19]. Ann Rheum Dis. 2021;annrheumdis-2020-219012.
doi:10.1136/annrheumdis-2020-219012
- Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of Filgotinib vs
Placebo on Clinical Response in Patients With Moderate to Severe
Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic
Drug Therapy: The FINCH 2 Randomized Clinical Trial [published
correction appears in JAMA. 2020 Feb 4;323(5):480]. JAMA .
2019;322(4):315-325. doi:10.1001/jama.2019.9055
- Westhovens R, Rigby W, van der Heijde D, Ching D, Bartok B, Matzkies
F, et al. Efficacy and Safety of Filgotinib for Patients with
Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH 3 Primary
Outcome Results. European Congress of Rheumatology. 12-15 June,
2019. Madrid, Spain; Abstract LB003.
- Feagan BG, Loftus Jr EV, Danese S, Vermeire S, Sandborn WJ, Ritter T,
Mehta R, Seidler U, Seibold F, Beales I, Kim H. A15 Efficacy And
Safety Of Filgotinib As Induction Therapy For Patients With Moderately
To Severely Active Ulcerative Colitis: Results From The Phase 2b/3
Selection Study. Journal of the Canadian Association of
Gastroenterology. 2021 Mar;4(Supplement_1):18-20.
- Peyrin-Biroulet L, Loftus Jr EV, Danese S, Vermeire S, Sandborn WJ,
Fogel R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, McNally J.
A17 Efficacy And Safety Of Filgotinib As Maintenance Therapy For
Patients With Moderately To Severely Active Ulcerative Colitis:
Results From The Phase 2b/3 Selection Study. Journal of the
Canadian Association of Gastroenterology. 2021
Mar;4(Supplement_1):21-3.
- Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in
patients with moderate-to-severe Crohn’s disease treated with
filgotinib (the FITZROY study): results from a phase 2, double-blind,
randomised, placebo-controlled trial. Lancet.2017;389(10066):266-275. doi:10.1016/S0140-6736(16)32537-5
- Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical
characterization of GLPG0634, a selective inhibitor of JAK1, for the
treatment of inflammatory diseases. J Immunol .
2013;191(7):3568-3577. doi:10.4049/jimmunol.1201348
- Namour F, Fagard L, Van der Aa A, Harrison P, Xin Y, Tasset C.
Influence of age and renal impairment on the steady state
pharmacokinetics of filgotinib, a selective JAK1 inhibitor. Br J
Clin Pharmacol . 2018;84(12):2779-2789. doi:10.1111/bcp.13726
- Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or
adalimumab in patients with rheumatoid arthritis and inadequate
response to methotrexate: a phase III randomised clinical trial
[published online ahead of print, 2021 Jan 27]. Ann Rheum
Dis . 2021;annrheumdis-2020-219214.
doi:10.1136/annrheumdis-2020-219214
- Westhovens R, Taylor PC, Alten R, et al. Filgotinib
(GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in
combination with methotrexate (MTX) in patients with active rheumatoid
arthritis and insufficient response to MTX: results from a randomised,
dose-finding study (DARWIN 1). Ann Rheum Dis .
2017;76(6):998-1008. doi:10.1136/annrheumdis-2016-210104
- Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034),
an oral selective JAK1 inhibitor, is effective as monotherapy in
patients with active rheumatoid arthritis: results from a randomised,
dose-finding study (DARWIN 2). Ann Rheum Dis .
2017;76(6):1009-1019. doi:10.1136/annrheumdis-2016-210105
- Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and
Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a
Selective JAK1 Inhibitor, in Support of Phase IIB Dose
Selection. Clin Pharmacokinet . 2015;54(8):859-874.
doi:10.1007/s40262-015-0240-z
- Anderson K, Zheng H, Kotecha M, et al. The Relative Bioavailability
and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in
Healthy Subjects. Clin Pharmacol Drug Dev . 2019;8(5):585-594.
doi:10.1002/cpdd.659
- Anderson K, Zheng H, Medzihradsky O, et al. THU0117 Pharmacokinetics
and short-term safety of filgotinib, a selective janus kinase 1
inhibitor, in subjects with moderate hepatic impairment. Annals
of the Rheumatic Diseases 2019;78: 331.
- Dosne AG, Bergstrand M, Harling K, Karlsson MO. Improving the
estimation of parameter uncertainty distributions in nonlinear mixed
effects models using sampling importance resampling. J
Pharmacokinet Pharmacodyn . 2016;43(6):583-596.
doi:10.1007/s10928-016-9487-8
Figure Legends
Figure 1. Exposure-response
relationship of AUCeff based on filgotinib and GS-829845 against ACR and
DAS28 (CRP) responses at Week 12 in subjects with RA in pooled Phase 2
and Phase 3 studies. The analysis set includes subjects with RA who were
enrolled/randomized, received at least 1 dose of filgotinib in studies
DARWIN 1, DARWIN 2, FINCH 1, FINCH 2, and FINCH 3, and had at least 1
nonmissing PK parameter of interest. Each symbol represents the
proportion of subjects achieving the ACR response with the vertical line
showing the 95% confidence interval within each group based on the
Clopper-Pearson method. Circles show ACR20, triangles show ACR50, and
squares show ACR70 in the left panel. Hollow circles show DAS28 ≤ 3.2
and hollow triangles show DAS28 < 2.6 in the right panel.
Shaded areas with blue stripes show median (dashed vertical line) and
fifth and 95th percentiles (dotted vertical lines) of AUCeff for
filgotinib 200 mg once daily in Phase 2 and Phase 3 subjects with RA;
shaded areas with pink cross pattern show median (dashed vertical line)
and fifth and 95th percentiles (dotted vertical lines) of AUCeff for
filgotinib 100 mg once daily in Phase 2 and Phase 3 subjects with RA.
AUCeff is based on the population PK‑predicted exposure in Phase 2 and
Phase 3 subjects with rheumatoid arthritis receiving filgotinib.
Figure
2.Exposure-response relationship of AUCeff based on filgotinib and
GS-829845 against ACR and das28 (CRP) responses at Week 24 in subjects
with RA in pooled Phase 2 and Phase 3 studies.
The
analysis set includes subjects with RA who were enrolled/randomized,
received at least 1 dose of filgotinib in studies DARWIN 1, DARWIN 2,
FINCH 1, FINCH 2, and FINCH 3, and had at least 1 nonmissing PK
parameter of interest. Each symbol represents the proportion of subjects
achieving the ACR response with the vertical line showing the 95%
confidence interval within each group based on the Clopper-Pearson
method. Circles show ACR20, triangles show ACR50, and squares show ACR70
in the left panel. Hollow circles show DAS28 ≤ 3.2 and hollow triangles
show DAS28 < 2.6 in the right panel. Shaded areas with blue
stripes show median (dashed vertical line) and fifth and 95th
percentiles (dotted vertical lines) of AUCeff for filgotinib 200 mg once
daily in Phase 2 and Phase 3 subjects with RA; shaded
areas with pink cross pattern show median (dashed vertical line) and
fifth and 95th percentiles (dotted vertical lines) of
AUCeff for filgotinib 100 mg once daily in Phase 2 and
Phase 3 subjects with RA. AUCeff is based on the
population PK‑predicted exposure in Phase 2 and Phase 3 subjects with
rheumatoid arthritis receiving filgotinib.
Figure 3.Boxplot
of AUCeff in subjects who achieved and did not achieve
ACR20/50/70 and DAS28 (CRP) responses in pooled Phase 2 and Phase 3
studies. PK/PD analysis set includes subjects with RA who were
enrolled/randomized, received at least 1 dose of filgotinib in studies
FINCH 1, 2, 3, and had at least 1 nonmissing PK parameter of interest.
For each box, the bottom and top edges are located at the sample 25th
(Q1) and 75th (Q3) percentiles, respectively; the center horizontal line
is drawn at the 50th percentile (median); and outliners (beyond 1.5 ×
the interquartile range) are displayed as small squares. ACR and DAS28
responses at Week 12 are shown in the upper panel and ACR and DAS28
responses at Week 24 are shown in the lower panel.
Figure
4.
Filgotinib
AUC0-24 by the 5 most frequent TEAEs in subjects with RA
up to Week 52 data.
The
analysis set includes subjects with RA who were enrolled/randomized,
received at least 1 dose of filgotinib in studies FINCH 1, FINCH 2 FINCH
3, DARWIN 1, DARWIN 2, DARWIN 3, and had at least 1 nonmissing PK
parameter of interest. For each box, the bottom and top edges are
located at the sample 25th (Q1) and 75th (Q3) percentiles, respectively;
the center horizontal line is drawn at the 50th percentile (median); and
outliners (beyond 1.5 × the interquartile range) are displayed as small
squares. AUC0-24 is the population PK-predicted exposure
in Phase 2and Phase 3 subjects with rheumatoid arthritis receiving
filgotinib.
Figure 5. GS-829845 AUC0-24 by the 5 most
frequent TEAEs in subjects with RA up to Week 52 data. The analysis set
includes subjects with RA who were enrolled/randomized, received at
least 1 dose of filgotinib in studies FINCH 1, FINCH 2 FINCH 3, DARWIN
1, DARWIN 2, DARWIN 3, and had at least 1 nonmissing PK parameter of
interest. For each box, the bottom and top edges are located at the
sample 25th (Q1) and 75th (Q3) percentiles, respectively; the center
horizontal line is drawn at the 50th percentile (median); and outliners
(beyond 1.5 × the interquartile range) are displayed as small squares.
AUC0-24 is the population PK-predicted exposure in Phase
2and Phase 3 subjects with rheumatoid arthritis receiving filgotinib.
Figure 6. Filgotinib
AUC0-24 by the 5 most frequent Grade 3/4 laboratory
abnormalities in subjects with RA. The analysis set includes subjects
with RA who were enrolled/randomized, received at least 1 dose of
filgotinib in studies FINCH 1, FINCH 2 FINCH 3, DARWIN 1, DARWIN 2,
DARWIN 3 and had at least 1 nonmissing PK parameter of interest. For
each box, the bottom and top edges are located at the sample 25th (Q1)
and 75th (Q3) percentiles, respectively; the center horizontal line is
drawn at the 50th percentile (median); and outliners (beyond 1.5 × the
interquartile range) are displayed as small squares.
AUC0-24 is the population PK-predicted exposure in Phase
2 and Phase 3 subjects with rheumatoid arthritis receiving filgotinib.
Figure
7.GS-829845 AUC0-24 by the 5 most frequent Grade 3/4
laboratory abnormalities in subjects with RA. The analysis set includes
subjects with RA who were enrolled/randomized, received at least 1 dose
of filgotinib in studies FINCH 1, FINCH 2 FINCH 3, DARWIN 1, DARWIN 2,
DARWIN 3, and had at least 1 nonmissing PK parameter of interest. For
each box, the bottom and top edges are located at the sample 25th (Q1)
and 75th (Q3) percentiles, respectively; the center horizontal line is
drawn at the 50th percentile (median); and outliners (beyond 1.5 × the
interquartile range) are displayed as small squares.
AUC0-24 is the population PK-predicted exposure in Phase
2 and Phase 3 subjects with rheumatoid arthritis receiving filgotinib.